Generic molecule: teriflunomide
Approval date: Sept. 12
The scoop: Soon after the news hit the wires that Sanofi ($SNY) had won a badly needed FDA approval for its oral multiple sclerosis drug Aubagio (teriflunomide), a rep for Sanofi subsidiary Genzyme began touting the price advantages. At $45,000 a year, the drug will be trying to grab market share from Copaxone, Avonex and Gilenya. Genzyme is also seeking approval of Lemtrada for MS, where it's been given a good shot, and if approved will contribute to the company's growing MS franchise.